Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
出版年份 2020 全文链接
标题
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
作者
关键词
-
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-06
DOI
10.1007/s00259-020-04828-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
- (2019) Alexander Heinzel et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting
- (2019) Martin Boegemann et al. Oncotarget
- 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
- (2019) Fadi Khreish et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer
- (2018) Yong Joong Kim et al. CLINICAL NUCLEAR MEDICINE
- Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
- (2018) Bernhard Grubmüller et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes
- (2018) John A Violet et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
- (2017) Axel Bräuer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer: Secondary analysis.
- (2017) Andrea Carolina Anampa-Guzman et al. JOURNAL OF CLINICAL ONCOLOGY
- Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
- (2017) Florian C. Gaertner et al. Oncotarget
- Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial
- (2016) Yohann Loriot et al. CANCER
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177 Lu-PSMA-617
- (2016) Justin Ferdinandus et al. JOURNAL OF NUCLEAR MEDICINE
- A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
- (2015) K. N. Chi et al. ANNALS OF ONCOLOGY
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- (2014) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer
- (2013) Gregory R. Pond et al. EUROPEAN UROLOGY
- Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2013) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
- (2013) O B Goodman et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Characterising the castration-resistant prostate cancer population: a systematic review
- (2011) M. Kirby et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation